Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release

Abstract

PSi represents a promising sustained and tailorable release system for PYY3-36.

Novel Delivery Systems for Improving the Clinical Use of Peptides

“…PSi differs from many of the commonly used drug carriers since the loading of peptides is much easier compared with, for example, typically used polymer materials, and there is no need to use conditions that can be harmful for peptides such as strong solvents or high temperatures. Our research group demonstrated the promising features of PSi for sustained delivery of peptides (Kilpeläinen et al, 2009;Kovalainen et al, 2012;Huotari et al, 2013). In the following sections, we give an overview on the PSi material and its use in peptide delivery where the subcutaneous route has shown to be the preferable administration route.…”

“…4). Kovalainen et al (2012) studied the loading efficiency of PYY 3-36 in PSi with three different surface chemistries (Fig. 5).…”

Drug Delivery with Porous Silicon

“…In 2007, Prestidge et al showed that a protein can be loaded and released from PSi (Prestidge et al 2007), and in 2009, Kilpel€ ainen et al showed in vivo that the loaded peptide was pharmacologically active after the loading (Kilpelainen et al 2009). In the following years, more results about subcutaneous administration of different peptides were published (Kilpelainen et al 2011;Kovalainen et al 2012Kovalainen et al , 2013. In addition to the remaining pharmacological activity, some other important findings were published recently.…”

Silicon-Based Nanoagents for Cancer Therapy

“…Since the first report revealing porous silicon particles-induced enhancement of paracellular delivery of insulin [25], sufficient advancement in developing pSi-based effective drug delivery systems for various kinds of therapeutic agents (e.g., pharmaceutical drugs (indomethacin (IMC) [26,27], doxorubicin (DOX) [28][29][30][31][32], paclitaxel [33], mitoxantrone dihydrochloride (MTX) [34,35], camptothecin (CPT) [36][37][38][39], and emodin [40]), therapeutic proteins (insulin [25,41], bovine serum albumin (BSA) [41], peptide [26,[42][43][44][45][46] ), and genes (siRNA [33,[47][48][49][50]), etc.) has been achieved in recent decades.…”